EDIT Editas Medicine, Inc. - Common Stock
$2,90
Preço · Ago 18, 2026
Fundamentais a partir de Ago 5, 2026
Intervalo 52 Semanas
$2–$5
43% of range
Classificação do Analista
BUY
18 analysts
Preço-Alvo
$6
+107% upside
P/E (TTM)
-1.6
ROE
-688.8%
Margem de Lucro Líquido
-395.0%
Sobre Editas Medicine, Inc. - Common Stock Visão geral da empresa da Wikipedia
Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
Ler mais
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
History
Editas Medicine was originally founded with the name "Gengine, Inc." in September 2013 by Feng Zhang of the Broad Institute, Jennifer Doudna of the University of California, Berkeley, and George Church, David Liu, and J. Keith Joung of Harvard University, with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures. The name was changed to the current "Editas Medicine" two months later. Doudna quit in June 2014 over legal differences concerning intellectual property of Cas9.
In August 2015, the company raised $120 million in Series B funding from Bill Gates and 13 other investors. it went public on 2 February 2016, via a $94 million initial public offering.
Editas entered into a strategic collaboration with Juno Therapeutics in 2015 to create a chimeric antigen receptor and high-affinity T cell receptor therapeutics to the end of developing cancer therapeutics. Juno was later acquired by Celgene, which was in turn acquired by Bristol Myers Squibb.
The company announced in 2015 that it was planning a clinical trial using CRISPR gene editing techniques to treat Leber congenital amaurosis type 10 (LCA10), a rare genetic illness that causes blindness. On 30 November 2018, the FDA gave permission to start the trials, under the investigational name EDIT-101 (also known as AGN-151587). In September 2021, a statement from Editas claimed that preliminary results from clinical trials were promising and support clinical benefits of EDIT-101 treatment.
In March 2020, Editas, in partnership with Allergan, was the first to use CRISPR to try to edit DNA inside a person's body (in vivo). As part of the clinical trial, a patient who was nearly blind as a result of Leber's congenital amaurosis received an intravitreal injection containing a harmless virus carrying CRISPR gene-editing instructions. Five months later, Editas reworked its deal with Allergan's owner AbbVie and regained full rights to their range of eye disease treatment therapies, including EDIT-101 for the treatment of LCA10.
In 2019, the company was building new chemistry facilities in Boulder, Colorado.
Katrine Bosley was CEO until 2019, when she was replaced by board member Cynthia Collins. Collins was replaced in 2021 by James Mullen, who had been board chairman. Gilmore O'Neill, former CMO of Sarepta Therapeutics, became CEO on June 1, 2022, with Mullen staying on as executive chairman of the board.
On December 12, 2024, Editas ended the development of reni-cel and laid off 65% of its employees.
Research
Editas works with two different CRISPR nucleases, Cas9 and Cas12a.
EDIT-101 is a CRISPR based gene therapy for treatment of Leber congenital amaurosis, currently in clinical trials.
EDIT-301 is an experimental potential treatment utilizing the firm's CAS 12a editing technology for sickle cell disease and beta-thalassemia. In 2019 the firm reported early success in research on the drug;. In December 2020, it filed an IND application for treatment of sickle cell disease. In January 2021, it said it had received clearance from the FDA for phase 1 safety studies.
== References ==
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
EDIT Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$2.90
Capitalização de Mercado
$284M
P/E (TTM)
-1.6
EPS (TTM)
$-1.80
Receita (TTM)
$41M
Rendimento div.
—
ROE
-688.8%
Dívida/Capital
2.1
Intervalo 52 Semanas
$2 – $5
EDIT Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Configure
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita e Lucro Líquido
$41M
2016-12-31
→
2025-12-31
EPS
$-1.80
2019-12-31
→
2025-12-31
Fluxo de caixa livre
$-166M
2016-12-31
→
2025-12-31
Margens
-395.0%
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Métrica
Tendência de 5 anos
EDIT
Mediana de Pares
P/E (TTM)
-1.6
17.4
P/S (TTM)
7.0
52.3
P/B
10.4
4.8
EV / EBITDA
-1.2
—
Price / FCF (Preço / FCF)
-1.7
—
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Métrica
Tendência de 5 anos
EDIT
Mediana de Pares
Operating Margin (Margem Operacional)
-394.9%
—
Net Profit Margin (Margem de Lucro Líquido)
-395.0%
-670.1%
ROA
-60.6%
-41.1%
ROE
-688.8%
-52.6%
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Métrica
Tendência de 5 anos
EDIT
Mediana de Pares
Debt / Equity (Dívida / Patrimônio Líquido)
2.1
—
Current Ratio (Índice de liquidez corrente)
3.5
7.7
Quick Ratio (Índice de Liquidez Seca)
3.5
—
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Métrica
Tendência de 5 anos
EDIT
Mediana de Pares
Revenue YoY (Receita Ano a Ano)
25.4%
—
Revenue CAGR 3Y (CAGR Receita 3A)
27.2%
—
Revenue CAGR 5Y (CAGR Receita 5A)
-14.9%
—
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Métrica
Tendência de 5 anos
EDIT
Mediana de Pares
EDIT Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
COMPRA
18 analistas
- Compra forte 4 22,2%
- Compra 8 44,4%
- Manter 4 22,2%
- Venda 2 11,1%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
8 analistas · 2026-08-16
Mediana
$5.00
Agora
$2.90
Mín
$1.00
Máx
$15.00
Alvo mediano
$5.00
+72,4%
Alvo médio
$6.00
+106,9%
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
-0.03%
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 30 de Junho de 2026 | $-0.15 | $-0.28 | 0.13% |
| 31 de Março de 2026 | $-0.26 | $-0.27 | 0.01% |
| 31 de Dezembro de 2025 | $-0.06 | $-0.26 | 0.20% |
| 30 de Setembro de 2025 | $-0.28 | $-0.30 | 0.02% |
| 30 de Junho de 2025 | $-0.63 | $-0.38 | -0.25% |
| 31 de Março de 2025 | $-0.92 | $-0.60 | -0.32% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| EDIT | $201M | -1.1 | 25.4% | -395.0% | -688.8% | — |
| LRMR | $317M | -2.2 | — | — | -167.4% | — |
| PBYI | $300M | 9.8 | -0.91% | 13.6% | 26.5% | — |
| RZLT | $388M | -4.6 | — | — | -56.9% | — |
| BNTC | $307M | -11.1 | — | — | -43.8% | — |
| CMPX | $958M | — | — | — | -45.9% | — |
| PROK | — | — | 1075.0% | -7725.2% | 6.9% | — |
| FENC | $263M | -22.6 | -6.1% | -21.8% | -69.6% | — |
| LXEO | $725M | -5.3 | — | — | -51.9% | — |
| CAPR | $1.66B | -12.8 | -11.6% | — | -51.1% | — |
| FHTX | $306M | -4.6 | 36.8% | -240.3% | 80.2% | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 13
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| R&D Expense | $90M | $199M | $178M | $175M | $143M | $158M | $97M | $91M | $83M | $57M | |
| SG&A Expense | $50M | $72M | $70M | $71M | $76M | $68M | $65M | $55M | $51M | $46M | |
| Operating Expenses | $201M | $283M | $247M | $246M | $219M | $226M | $161M | $146M | $134M | $103M | |
| Operating Income | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M | |
| Other Non-op | $-2M | $-3.0K | $-2M | $0 | $37.0K | $16M | $-137.0K | $328.0K | $587.0K | $-57.0K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | |
| Net Income | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| EPS (Basic) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| EPS (Diluted) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| Shares (Basic) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| Shares (Diluted) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| EBITDA | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M |
Balanço Patrimonial 24
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $147M | $132M | $124M | $142M | $204M | $140M | $238M | $135M | $147M | $185M | |
| Short-term Investments | $0 | $138M | $199M | $203M | $296M | $262M | $219M | $234M | $183M | · | |
| Receivables | $15M | $16M | $10M | $5M | $267.0K | $6M | $418.0K | $30.0K | $679.0K | $88.0K | |
| Prepaid Expense | $2M | $3M | $8M | $7M | $7M | $11M | $6M | $6M | $2M | $2M | |
| Current Assets | $164M | $289M | $341M | $357M | $507M | $419M | $464M | $375M | $332M | $187M | |
| PP&E (Net) | $4M | $14M | $12M | $16M | $17M | $14M | $11M | $40M | $39M | $40M | |
| PP&E (Gross) | $32M | $46M | $38M | $37M | $33M | $25M | $18M | $47M | $44M | $42M | |
| Accum. Depreciation | $28M | $32M | $26M | $22M | $16M | $11M | $7M | $7M | $4M | $2M | |
| Other Non-current Assets | $3M | $5M | $9M | $5M | $7M | $5M | $5M | $5M | $2M | $2M | |
| Total Assets | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Accounts Payable | $3M | $5M | $8M | $10M | $5M | $6M | $6M | $5M | $4M | $5M | |
| Accrued Liabilities | $33M | $46M | $35M | $31M | $20M | $24M | $22M | $13M | $11M | $17M | |
| Current Liabilities | $46M | $77M | $63M | $60M | $47M | $58M | $60M | $36M | $37M | $33M | |
| Capital Leases | $12M | $20M | $24M | $33M | $16M | $19M | $23M | $32M | $33M | $35M | |
| Other Non-current Liabilities | $3M | $3M | $2M | $0 | · | $28M | $1.0K | $293.0K | $317.0K | $396.0K | |
| Total Liabilities | $159M | $207M | $150M | $154M | $124M | $179M | $246M | $184M | $165M | $95M | |
| Long-term Debt | $59M | $57M | $0 | · | · | · | · | · | · | · | |
| Total Debt | $59M | $57M | · | · | · | · | · | · | · | · | |
| Common Stock | $10.0K | $8.0K | $8.0K | $7.0K | $7.0K | $6.0K | $5.0K | $5.0K | $4.0K | $4.0K | |
| Retained Earnings | $-1.63B | $-1.47B | $-1.23B | $-1.08B | $-858M | $-665M | $-549M | $-416M | $-306M | $-186M | |
| AOCI | $0 | $268.0K | $198.0K | $-4M | $-493.0K | $-46.0K | $107.0K | $-29.0K | $-76.0K | · | |
| Stockholders' Equity | $27M | $134M | $349M | $361M | $554M | $394M | $262M | $236M | $208M | $135M | |
| Liabilities + Equity | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Shares Outstanding | 97,866,996 | 82,734,696 | 81,767,263 | 68,847,382 | 68,435,257 | 62,563,457 | 54,355,798 | 48,758,951 | 44,507,960 | 35,818,131 |
Fluxo de Caixa 10
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $10M | $21M | $20M | $29M | $43M | $23M | $27M | $27M | $23M | $17M | |
| Restructuring | · | $12M | $0 | $0 | · | · | · | · | · | · | |
| Operating Cash Flow | $-165M | $-210M | $-132M | $-177M | $-164M | $-180M | $-41M | $-46M | $-9M | $-50M | |
| CapEx | $607.0K | $9M | $5M | $4M | $8M | $7M | $6M | $5M | $2M | $3M | |
| Investing Cash Flow | $139M | $162M | $-4M | $114M | $-54M | $-141M | $12M | $-53M | $-184M | $-3M | |
| Stock Issued | $43M | $0 | $117M | $0 | $249M | $204M | $116M | $77M | $154M | $97M | |
| Net Stock Activity | $43M | $0 | $117M | · | $249M | $204M | $116M | $77M | $154M | $97M | |
| Financing Cash Flow | $40M | $56M | $118M | $1M | $282M | $224M | $132M | $87M | $155M | $97M | |
| Net Change in Cash | $14M | $8M | $-18M | $-62M | $64M | $-96M | $103M | $-12M | $-39M | $43M | |
| Free Cash Flow | $-166M | $-219M | $-137M | $-181M | $-172M | $-187M | $-47M | $-50M | $-11M | $-53M |
Lucratividade 5
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| Net Margin | -395.0% | -733.7% | -196.1% | -1118.3% | -753.6% | -127.8% | -651.4% | -344.3% | · | · | |
| EBITDA Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| ROA | -60.6% | -56.4% | -30.2% | -37.0% | -30.8% | -21.4% | -28.8% | -27.7% | -40.0% | -51.3% | |
| ROE | -688.8% | -153.0% | -43.2% | -56.9% | -33.8% | -27.8% | -56.6% | -47.7% | -70.2% | -377.5% |
Liquidez e Solvência 4
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 | 7.2 | 7.7 | 10.4 | 9.1 | 5.7 | |
| Quick Ratio | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 | 7.0 | 7.6 | 10.3 | 9.0 | 5.6 | |
| Debt / Equity | 2.1 | 0.4 | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 2.0 | 0.4 | · | · | · | · | · | · | · | · |
Eficiência 2
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.1 | · | · | |
| Receivables Turnover | 2.6 | 2.4 | 10.2 | 7.3 | 8.1 | 28.1 | 91.7 | 90.1 | · | · |
Taxas de Crescimento 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 25.4% | -58.6% | 296.3% | -22.8% | -71.9% | · | · | · | · | · | |
| Revenue CAGR 3Y | 27.2% | 8.2% | -4.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -14.9% | · | · | · | · | · | · | · | · | · |
Avaliação (TTM) 14
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| Net Income TTM | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| Market Cap | $201M | $105M | $828M | $611M | $1.82B | $4.39B | $1.61B | $1.11B | $1.37B | $581M | |
| Enterprise Value | $113M | $-107M | · | · | · | · | · | · | · | · | |
| P/E | -1.1 | -0.4 | -5.0 | -2.8 | -9.3 | -35.4 | -11.0 | · | · | · | |
| P/S | 5.0 | 3.3 | 10.6 | 31.0 | 71.1 | 48.3 | 78.4 | 34.7 | 99.6 | 96.0 | |
| P/B | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | 6.1 | 4.7 | 6.6 | 4.3 | |
| P / Tangible Book | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | · | · | · | · | |
| P / Cash Flow | -1.2 | -0.5 | -6.3 | -3.4 | -11.1 | -24.4 | -39.6 | -24.3 | -145.2 | -11.6 | |
| P / FCF | -1.2 | -0.5 | -6.1 | -3.4 | -10.6 | -23.5 | -34.4 | -22.0 | -119.2 | -10.9 | |
| EV / EBITDA | -0.7 | 0.4 | · | · | · | · | · | · | · | · | |
| EV / FCF | -0.7 | 0.5 | · | · | · | · | · | · | · | · | |
| EV / Revenue | 2.8 | -3.3 | · | · | · | · | · | · | · | · | |
| Earnings Yield | -87.8% | -226.8% | -19.9% | -36.2% | -10.7% | -2.8% | -9.0% | · | · | · |
Demonstração de Resultados 12
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12M | $3M | $25M | $8M | $4M | $5M | $31M | $61.0K | $513.0K | $1M | $60M | $5M | $3M | $10M | $7M | $42.0K | |
| R&D Expense | $20M | $18M | $27M | $20M | $16M | $27M | $49M | $48M | $54M | $49M | $70M | $41M | $30M | $38M | $52M | $41M | |
| SG&A Expense | $12M | $10M | $11M | $12M | $13M | $13M | $16M | $18M | $18M | $19M | $14M | $15M | $17M | $23M | $18M | $16M | |
| Operating Expenses | $30M | $28M | $32M | $32M | $55M | $81M | $77M | $66M | $72M | $68M | $84M | $55M | $47M | $61M | $70M | $58M | |
| Operating Income | $-19M | $-25M | $-8M | $-25M | $-52M | $-76M | $-47M | $-66M | $-72M | $-67M | $-24M | $-50M | $-44M | $-51M | $-63M | $-58M | |
| Other Non-op | $17.0K | $-113.0K | $-5.0K | $-1.0K | $-2M | $-425.0K | $-3.0K | $-5.0K | $-1.0K | $6.0K | $-13.0K | $0 | $-7.0K | $-2M | $-2.0K | $1.0K | |
| Net Income | $-18M | $-25M | $-6M | $-25M | $-53M | $-76M | $-45M | $-62M | $-68M | $-62M | $-19M | $-45M | $-40M | $-49M | $-61M | $-56M | |
| EPS (Basic) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.88 | $-0.81 | |
| EPS (Diluted) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.88 | $-0.81 | |
| Shares (Basic) | 119,294,615 | 97,879,343 | -168,811,755 | 90,090,397 | 84,412,200 | 83,055,066 | -164,396,186 | 82,485,199 | 82,310,368 | 81,938,839 | -145,983,475 | 81,648,250 | 71,376,678 | 68,924,180 | -137,197,139 | 68,736,125 | |
| Shares (Diluted) | 119,294,615 | 97,879,343 | -168,811,755 | 90,090,397 | 84,412,200 | 83,055,066 | -164,396,186 | 82,485,199 | 82,310,368 | 81,938,839 | -145,983,475 | 81,648,250 | 71,376,678 | 68,924,180 | -137,197,139 | 68,736,125 | |
| EBITDA | $-19M | $-25M | · | $-25M | $-52M | $-76M | · | $-66M | $-72M | $-67M | · | $-50M | $-44M | $-51M | · | $-58M |
Balanço Patrimonial 24
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $182M | $124M | $147M | $166M | $139M | $139M | $132M | $96M | $64M | $69M | $124M | $83M | $221M | $129M | $142M | $211M | |
| Short-term Investments | $30M | · | $0 | $0 | $40M | $82M | $138M | $169M | $215M | $227M | $199M | $267M | $211M | $189M | · | $209M | |
| Receivables | $3M | $3M | $15M | $8M | $588.0K | $510.0K | $16M | $126.0K | $244.0K | $245.0K | $10M | $2M | $2M | $242.0K | · | $120.0K | |
| Prepaid Expense | $4M | $2M | $2M | $3M | $4M | $3M | $3M | $6M | $7M | $9M | $8M | $7M | $7M | $6M | · | $7M | |
| Current Assets | $218M | $128M | $164M | $177M | $183M | $225M | $289M | $271M | $286M | $306M | $341M | $359M | $441M | $324M | · | $427M | |
| PP&E (Net) | $3M | $3M | $4M | $4M | $5M | $8M | $14M | $15M | $14M | $13M | $12M | $12M | $13M | $13M | · | $15M | |
| PP&E (Gross) | $29M | $29M | $32M | $32M | $31M | $36M | $46M | $46M | $43M | $41M | $38M | $37M | $36M | $35M | · | $36M | |
| Accum. Depreciation | $27M | $26M | $28M | $28M | $27M | $28M | $32M | $31M | $29M | $28M | $26M | $25M | $23M | $22M | · | $20M | |
| Other Non-current Assets | $3M | $3M | $3M | $3M | $4M | $4M | $5M | $5M | $8M | $9M | $9M | $6M | $5M | $7M | · | $8M | |
| Total Assets | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | · | $531M | |
| Accounts Payable | $5M | $4M | $3M | $3M | $7M | $5M | $5M | $12M | $14M | $8M | $8M | $10M | $8M | $9M | · | $7M | |
| Accrued Liabilities | $17M | $21M | $33M | $48M | $48M | $47M | $46M | $29M | $28M | $31M | $35M | $30M | $28M | $32M | · | $19M | |
| Current Liabilities | $68M | $40M | $46M | $62M | $66M | $73M | $77M | $72M | $74M | $66M | $63M | $59M | $55M | $57M | · | $42M | |
| Capital Leases | $9M | $11M | $12M | $14M | $15M | $18M | $20M | $22M | $21M | $22M | $24M | $25M | $27M | $29M | · | $9M | |
| Other Non-current Liabilities | $2M | $3M | $3M | $5M | $5M | $6M | $3M | $3M | $4M | $3M | $2M | · | · | · | · | · | |
| Total Liabilities | $132M | $145M | $159M | $188M | $191M | $201M | $207M | $152M | $153M | $146M | $150M | $144M | $142M | $147M | · | $116M | |
| Long-term Debt | $56M | $55M | $59M | $59M | $57M | $55M | $57M | · | · | · | $0 | · | · | · | · | · | |
| Total Debt | $56M | $55M | · | $59M | $57M | $55M | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $15.0K | $10.0K | $10.0K | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $7.0K | · | $7.0K | |
| Retained Earnings | $-1.67B | $-1.65B | $-1.63B | $-1.62B | $-1.60B | $-1.54B | $-1.47B | $-1.42B | $-1.36B | $-1.29B | $-1.23B | $-1.21B | $-1.17B | $-1.13B | · | $-1.02B | |
| AOCI | $-6.0K | $0 | $0 | $0 | $15.0K | $88.0K | $268.0K | $522.0K | $-442.0K | $-326.0K | $198.0K | $-1M | $-2M | $-2M | · | $-4M | |
| Stockholders' Equity | $105M | $4M | $27M | $13M | $19M | $62M | $134M | $176M | $232M | $294M | $349M | $360M | $400M | $317M | $361M | $415M | |
| Liabilities + Equity | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | · | $531M | |
| Shares Outstanding | 97,866,996 | 97,866,996 | 97,866,996 | 93,264,421 | 87,388,425 | 83,709,536 | 82,734,696 | 82,538,624 | 82,429,514 | 82,234,951 | 81,767,263 | 81,668,796 | 81,616,909 | 68,993,591 | · | 68,761,729 |
Fluxo de Caixa 10
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $2M | $2M | $3M | $3M | $4M | $5M | $5M | $8M | $5M | $5M | $5M | $5M | $5M | $6M | |
| Restructuring | · | · | · | · | · | $53M | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-30M | $-23M | $-36M | $-31M | $-50M | $-48M | $-51M | $-53M | $-57M | $-50M | $-22M | $-35M | $-39M | $-36M | $-42M | $-48M | |
| CapEx | $106.0K | $92.0K | $60.0K | $433.0K | $0 | $114.0K | $540.0K | $3M | $3M | $2M | $1M | $239.0K | $1M | $2M | $624.0K | $614.0K | |
| Investing Cash Flow | $-30M | $64.0K | $58.0K | $40M | $43M | $56M | $31M | $84M | $52M | $-5M | $63M | $-103M | $13M | $23M | $-28M | $89M | |
| Stock Issued | $117M | $0 | $17M | $17M | $7M | $1M | $0 | $0 | $0 | $0 | $0 | $0 | · | · | $0 | · | |
| Net Stock Activity | · | $0 | · | · | · | $1M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $118M | $0 | $17M | $17M | $7M | $-1M | $56M | $0 | $322.0K | $192.0K | $514.0K | $0 | $118M | $0 | $619.0K | $80.0K | |
| Net Change in Cash | $58M | $-23M | $-19M | $26M | $-150.0K | $7M | $36M | $31M | $-5M | $-54M | $41M | $-138M | $92M | $-13M | $-69M | $41M | |
| Free Cash Flow | · | $-23M | · | · | · | $-48M | · | · | · | $-52M | · | · | · | $-38M | · | · |
Lucratividade 5
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | · | -136952.4% | |
| Net Margin | -153.3% | -882.4% | · | -333.0% | -1487.8% | -1633.5% | · | -101870.5% | -13178.8% | -5458.1% | · | -843.7% | -1395.6% | -497.8% | · | -132681.0% | |
| EBITDA Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | · | -136952.4% | |
| ROA | -8.1% | -12.1% | · | -9.5% | -17.9% | -21.6% | · | -14.9% | -14.6% | -13.7% | · | -8.7% | -7.2% | -9.0% | · | -8.9% | |
| ROE | -29.3% | -74.8% | · | -26.6% | -42.4% | -42.6% | · | -23.2% | -21.4% | -20.2% | · | -11.6% | -9.3% | -11.8% | · | -11.1% |
Liquidez e Solvência 4
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.2 | 3.2 | · | 2.9 | 2.8 | 3.1 | · | 3.7 | 3.9 | 4.6 | · | 6.1 | 8.1 | 5.7 | · | 10.1 | |
| Quick Ratio | 3.1 | 3.2 | · | 2.8 | 2.7 | 3.0 | · | 3.7 | 3.8 | 4.5 | · | 6.0 | 8.0 | 5.6 | · | 9.9 | |
| Debt / Equity | 0.5 | 12.4 | · | 4.4 | 3.0 | 0.9 | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.5 | 10.7 | · | 4.0 | 2.7 | 0.8 | · | · | · | · | · | · | · | · | · | · |
Eficiência 2
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 7.2 | 1.8 | · | 1.8 | 8.6 | 12.3 | · | 0.0 | 0.4 | 4.7 | · | 4.2 | 1.9 | 12.2 | · | 0.2 |
Avaliação (TTM) 14
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $26M | $19M | · | $16M | $9M | $6M | · | $7M | $10M | $19M | · | $18M | $19M | $23M | · | $19M | |
| Net Income TTM | $-122M | $-179M | · | $-217M | $-259M | $-268M | · | $-237M | $-215M | $-196M | · | $-190M | $-199M | $-209M | · | $-199M | |
| Market Cap | $317M | $242M | · | $324M | $192M | $97M | · | $281M | $385M | $610M | · | $637M | $672M | $500M | · | $842M | |
| Enterprise Value | $161M | $173M | · | $217M | $70M | $-69M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -2.5 | -1.2 | · | -1.3 | -0.7 | -0.4 | · | -1.2 | -1.7 | -2.9 | · | -3.0 | -2.9 | -2.4 | · | -4.2 | |
| P/S | 12.3 | 13.0 | · | 20.4 | 21.8 | 15.3 | · | 40.0 | 39.0 | 31.8 | · | 35.2 | 35.1 | 21.7 | · | 43.4 | |
| P/B | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | · | 2.0 | |
| P / Tangible Book | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | · | 2.0 | |
| P / Cash Flow | · | -10.5 | · | · | · | -2.0 | · | · | · | -12.2 | · | · | · | -14.0 | · | · | |
| P / FCF | · | -10.4 | · | · | · | -2.0 | · | · | · | -11.8 | · | · | · | -13.3 | · | · | |
| EV / EBITDA | -8.7 | -6.9 | · | -8.8 | -1.4 | 0.9 | · | · | · | · | · | · | · | · | · | · | |
| EV / FCF | · | -7.5 | · | · | · | 1.4 | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 6.2 | 9.3 | · | 13.7 | 8.0 | -10.9 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -40.7% | -84.6% | · | -74.4% | -141.8% | -280.2% | · | -84.5% | -57.6% | -34.8% | · | -33.7% | -34.8% | -41.9% | · | -23.7% |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Receita | $41M | $32M | $78M | $20M | $26M |
| Margem Operacional % | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% |
| Lucro líquido | $-160M | $-237M | $-153M | $-220M | $-193M |
| EPS Diluído | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido | 2.1 | 0.4 | — | — | — |
| Índice de liquidez corrente | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 |
| Índice de Liquidez Seca | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 |
Fluxo de Caixa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $-166M | $-219M | $-137M | $-181M | $-172M |
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
📊
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 239 declarantes · $327.2M total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 41 (+2 vs trimestre anterior) | 22 (-4 vs trimestre anterior) | 76 (+20 vs trimestre anterior) | 42 (-9 vs trimestre anterior) | +75.4M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| TCG Crossover Management, LLC | $36.000.000 | 11.111.111 | 11,00% | Ações |
| RA CAPITAL MANAGEMENT, L.P. | $28.800.360 | 8.889.000 | 8,80% | Ações |
| Commodore Capital LP | $28.800.360 | 8.889.000 | 8,80% | Ações |
| ADAR1 Capital Management, LLC | $28.800.360 | 8.889.000 | 8,80% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $19.897.929 | 6.141.336 | 6,08% | Ações |
| Paradigm Biocapital Advisors LP | $18.100.665 | 5.586.625 | 5,53% | Ações |
| Opaleye Management Inc. | $12.512.653 | 3.861.930 | 3,82% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $11.658.618 | 3.598.339 | 3,56% | Ações |
| Woodline Partners LP | $11.519.810 | 3.555.497 | 3,52% | Ações |
| Vivo Capital, LLC | $11.519.010 | 3.555.250 | 3,52% | Ações |
| GordonMD Global Investments LP | $10.131.480 | 3.127.000 | 3,10% | Ações |
| RENAISSANCE TECHNOLOGIES LLC | $7.999.298 | 2.468.919 | 2,45% | Ações |
| Logos Global Management LP | $7.199.280 | 2.222.000 | 2,20% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $7.134.030 | 2.201.290 | 2,18% | Ações |
| STATE STREET CORP | $7.101.442 | 2.191.803 | 2,17% | Ações |
| GOLDMAN SACHS GROUP INC | $6.763.843 | 2.087.606 | 2,07% | Ações |
| TWO SIGMA INVESTMENTS, LP | $4.318.842 | 1.332.976 | 1,32% | Ações |
| Seven Fleet Capital Management LP | $4.310.820 | 1.330.500 | 1,32% | Ações |
| RAYMOND JAMES FINANCIAL INC | $4.201.156 | 1.296.653 | 1,28% | Ações |
| MARSHALL WACE, LLP | $4.044.048 | 1.248.163 | 1,24% | Ações |
| D. E. Shaw & Co., Inc. | $3.715.178 | 1.146.660 | 1,14% | Ações |
| KENNEDY CAPITAL MANAGEMENT LLC | $3.344.111 | 1.032.133 | 1,02% | Ações |
| MACKENZIE FINANCIAL CORP | $2.844.856 | 878.042 | 0,87% | Ações |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $2.812.424 | 868.032 | 0,86% | Ações |
| Nantahala Capital Management, LLC | $2.762.748 | 852.700 | 0,84% | Ações |
| TWO SIGMA ADVISERS, LP | $2.509.405 | 1.224.100 | 0,77% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $2.407.158 | 742.950 | 0,74% | Ações |
| BlackRock, Inc. | $1.813.920 | 559.852 | 0,55% | Ações |
| MILLENNIUM MANAGEMENT LLC | $1.616.750 | 498.997 | 0,49% | Ações |
| Susquehanna Portfolio Strategies, LLC | $1.545.801 | 477.099 | 0,47% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.521.180 | 469.500 | 0,46% | Opção de compra |
| Eversept Partners, LP | $1.486.541 | 458.809 | 0,45% | Ações |
| Casdin Capital, LLC | $1.441.800 | 445.000 | 0,44% | Ações |
| PEAK6 LLC | $1.346.029 | 415.441 | 0,41% | Ações |
| DIADEMA PARTNERS LP | $1.296.000 | 400.000 | 0,40% | Opção de compra |
| BIT Capital GmbH | $1.056.240 | 326.000 | 0,32% | Ações |
| Cubist Systematic Strategies, LLC | $994.094 | 286.482 | 0,30% | Ações |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $878.642 | 271.186 | 0,27% | Ações |
| BANK OF AMERICA CORP /DE/ | $751.119 | 231.827 | 0,23% | Ações |
| LPL Financial LLC | $748.813 | 231.115 | 0,23% | Ações |
| Erste Asset Management GmbH | $736.000 | 230.000 | 0,22% | Ações |
| IEQ CAPITAL, LLC | $705.623 | 217.785 | 0,22% | Ações |
| Walleye Capital LLC | $595.703 | 183.859 | 0,18% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $558.900 | 172.500 | 0,17% | Opção de venda |
| CITADEL ADVISORS LLC | $557.604 | 172.100 | 0,17% | Opção de venda |
| DAFNA Capital Management LLC | $552.323 | 170.470 | 0,17% | Ações |
| Mariner, LLC | $548.500 | 169.291 | 0,17% | Ações |
| Green Alpha Advisors, LLC | $505.589 | 156.046 | 0,15% | Ações |
| PEAK6 LLC | $497.340 | 153.500 | 0,15% | Opção de compra |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $490.555 | 151.406 | 0,15% | Ações |
| BARCLAYS PLC | $476.030 | 146.923 | 0,15% | Ações |
| ALLIANCEBERNSTEIN L.P. | $464.187 | 187.930 | 0,14% | Ações |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $445.030 | 137.355 | 0,14% | Ações |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $408.240 | 126.000 | 0,12% | Ações |
| Point72 Asset Management, L.P. | $405.758 | 125.234 | 0,12% | Ações |
| RHUMBLINE ADVISERS | $380.421 | 117.417 | 0,12% | Ações |
| JPMORGAN CHASE & CO | $376.528 | 117.665 | 0,12% | Ações |
| JANE STREET GROUP, LLC | $374.473 | 115.578 | 0,11% | Ações |
| FMR LLC | $348.384 | 107.526 | 0,11% | Ações |
| HSBC HOLDINGS PLC | $314.481 | 97.062 | 0,10% | Ações |
| Bank of New York Mellon Corp | $309.378 | 95.487 | 0,09% | Ações |
| WELLINGTON MANAGEMENT GROUP LLP | $303.462 | 93.661 | 0,09% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $300.818 | 92.845 | 0,09% | Ações |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $300.226 | 92.094 | 0,09% | Ações |
| AMERICAN CENTURY COMPANIES INC | $300.011 | 92.596 | 0,09% | Ações |
| CWM, LLC | $259.352 | 105.001 | 0,08% | Ações |
| MORGAN STANLEY | $237.324 | 73.248 | 0,07% | Ações |
| CITADEL ADVISORS LLC | $229.392 | 70.800 | 0,07% | Opção de compra |
| OSAIC HOLDINGS, INC. | $222.928 | 68.806 | 0,07% | Ações |
| SEI INVESTMENTS CO | $221.188 | 68.268 | 0,07% | Ações |
| Nuveen, LLC | $221.188 | 68.268 | 0,07% | Ações |
| Joel Isaacson & Co., LLC | $220.787 | 68.144 | 0,07% | Ações |
| JANE STREET GROUP, LLC | $218.376 | 67.400 | 0,07% | Opção de venda |
| SIMPLEX TRADING, LLC | $207.275 | 63.974 | 0,06% | Ações |
| MetLife Investment Management, LLC | $182.140 | 56.216 | 0,06% | Ações |
| CITIGROUP INC | $182.052 | 56.189 | 0,06% | Ações |
| CITADEL ADVISORS LLC | $173.923 | 53.680 | 0,05% | Ações |
| MML INVESTORS SERVICES, LLC | $168.765 | 52.088 | 0,05% | Ações |
| GROUP ONE TRADING LLC | $163.131 | 50.349 | 0,05% | Ações |
| Creative Planning | $147.653 | 45.572 | 0,05% | Ações |
| China Universal Asset Management Co., Ltd. | $143.934 | 44.424 | 0,04% | Ações |
| WINTON GROUP Ltd | $141.588 | 43.700 | 0,04% | Ações |
| Vanguard Global Advisers, LLC | $138.876 | 42.863 | 0,04% | Ações |
| CANADA PENSION PLAN INVESTMENT BOARD | $137.376 | 42.400 | 0,04% | Ações |
| Graham Capital Management, L.P. | $134.369 | 41.472 | 0,04% | Ações |
| Quinn Opportunity Partners LLC | $129.600 | 40.000 | 0,04% | Ações |
| Invesco Ltd. | $128.178 | 39.561 | 0,04% | Ações |
| Vanguard Personalized Indexing Management, LLC | $124.108 | 38.305 | 0,04% | Ações |
| MERCER GLOBAL ADVISORS INC /ADV | $121.967 | 37.644 | 0,04% | Ações |
| Balyasny Asset Management L.P. | $121.947 | 37.638 | 0,04% | Ações |
| AXQ CAPITAL, LP | $118.104 | 36.452 | 0,04% | Ações |
| Nuveen Asset Management, LLC | $113.934 | 89.712 | 0,03% | Ações |
| SCS Capital Management LLC | $113.400 | 35.000 | 0,03% | Ações |
| Police & Firemen's Retirement System of New Jersey | $109.749 | 33.873 | 0,03% | Ações |
| Thrive Wealth Management, LLC | $108.540 | 33.500 | 0,03% | Ações |
| TWO SIGMA SECURITIES, LLC | $107.367 | 33.138 | 0,03% | Ações |
| INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | $102.359 | 31.207 | 0,03% | Ações |
| CAPTRUST FINANCIAL ADVISORS | $98.159 | 30.296 | 0,03% | Ações |
| HORIZON KINETICS ASSET MANAGEMENT LLC | $89.683 | 27.680 | 0,03% | Ações |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $88.339 | 27.265 | 0,03% | Ações |
Executivos da empresa 32 insiders · 13 diretores · 15 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Gilmore Neil O'Neill | CEO | 3 de Junho de 2026 S | 248.313 | 0 | 1 | $-41.543 |
| MULLEN JAMES C | CEO | 3 de Janeiro de 2022 S | 75.898 | 0 | 0 | $0 |
| Cynthia Collins | CEO | 9 de Fevereiro de 2021 S | 43.760 | 0 | 0 | $0 |
| Katrine Bosley | President and CEO | 8 de Janeiro de 2019 S | 1.204.966 | 0 | 0 | $0 |
| Michelle Robertson | Chief Financial Officer | 11 de Janeiro de 2022 S | 31.462 | 0 | 0 | $0 |
| Andrew A. F. Hack | Chief Financial Officer | 4 de Fevereiro de 2019 M | 0 | 0 | 0 | $0 |
| Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | 28 de Julho de 2026 S | 62.369 | 0 | 2 | $-15.133 |
| Bruce Eaton | EVP, Chief Business Officer | 22 de Dezembro de 2021 A | 31.498 | 0 | 0 | $0 |
| Lisa Anne Michaels | EVP/Chief Medical Officer | 22 de Dezembro de 2021 A | 22.675 | 0 | 0 | $0 |
| Mark S Shearman | EVP, Chief Scientific Officer | 22 de Dezembro de 2021 A | 41.785 | 0 | 0 | $0 |
| Judith R Abrams | Chief Medical Officer | 28 de Outubro de 2019 A | 25.000 | 0 | 0 | $0 |
| Vickesh Myer | Chief Technology Officer | 18 de Março de 2019 M | 0 | 0 | 0 | $0 |
| Gerald Frank Cox | Chief Medical Officer | 7 de Fevereiro de 2018 A | 4.000 | 0 | 0 | $0 |
| Elliott M. Levy | Conselheiro | 17 de Junho de 2026 A | — | 0 | 0 | $0 |
| David Scadden | Conselheiro | 17 de Junho de 2026 A | — | 0 | 0 | $0 |
| Bernadette Connaughton | Conselheiro | 17 de Junho de 2026 A | — | 0 | 0 | $0 |
| Jessica Hopfield | Conselheiro | 17 de Junho de 2026 A | 22.700 | 0 | 0 | $0 |
| Andrew Hirsch | Conselheiro | 17 de Junho de 2026 A | — | 0 | 0 | $0 |
| Emma Reeve | Conselheiro | 3 de Setembro de 2021 A | — | 0 | 0 | $0 |
| Meeta Chatterjee | Conselheiro | 3 de Junho de 2021 A | — | 0 | 0 | $0 |
| Boris Nikolic | Conselheiro | 15 de Junho de 2018 A | 35.000 | 0 | 0 | $0 |
| Douglas G. Cole | Conselheiro | 17 de Agosto de 2017 J | 3.171 | 0 | 0 | $0 |
| Kevin Bitterman | Conselheiro | 15 de Junho de 2017 A | 2.797.144 | 0 | 0 | $0 |
| Alexis Borisy | Conselheiro | 15 de Junho de 2017 A | 0 | 0 | 0 | $0 |
| John Mendlein | Conselheiro | 15 de Junho de 2017 A | — | 0 | 0 | $0 |
| Kevin P Starr | Detentor de 10% | 6 de Setembro de 2016 S | 0 | 0 | 0 | $0 |
| bng0, LLC | Detentor de 10% | 8 de Fevereiro de 2016 C | 2.649.572 | 0 | 0 | $0 |
| Patrick Thomas Ellinor II | — | 6 de Agosto de 2026 A | — | 0 | 0 | $0 |
| Amy Parison | — | 3 de Agosto de 2026 S | 14.292 | 0 | 2 | $-3.002 |
| Akshay Vaishnaw | — | 3 de Junho de 2021 A | — | 0 | 0 | $0 |
| Charles Albright | — | 15 de Dezembro de 2020 M | 24.907 | 0 | 0 | $0 |
| Alexandra Glucksmann | — | 15 de Março de 2017 M | 117.788 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Ativistas e proprietários de 5%+ 1 participação
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Polaris Venture Partners VI, L.P. (“PVP VI”), Polaris Venture Founders’ Fund VI, L.P. (“PVPFF VI”), Polaris Venture Management Co. VI, L.L.C. (“PVM VI”), Jonathan A. Flint (“Flint”), Terrance G. McGuire (“McGuire”), Brian Chee (“Chee”), David Barrett (“Barrett”), Amir Nashat (“Nashat”), Bryce Youngren (“Youngren”) ×4 declarações | 18 de Setembro de 2017 | — | Declaração inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Participação em ETFs Detido por 28 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,41% | 32.319 SH | 8 de Agosto de 2026 | Diário |
| GNOM · Global X Funds | 0,34% | 54.725 NS | 31 de Maio de 2026 | N-PORT |
| IWC · iShares Trust | 0,07% | 341.978 SH | 8 de Agosto de 2026 | Diário |
| IBB · iShares Trust | 0,03% | 1.035.067 SH | 8 de Agosto de 2026 | Diário |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,03% | 8.268 SH | 8 de Agosto de 2026 | Diário |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,02% | 96.927 SH | 8 de Agosto de 2026 | Diário |
| BIB · ProShares Trust | 0,02% | 3.611 NS | 31 de Maio de 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 0,02% | 1.527 NS | 31 de Maio de 2026 | N-PORT |
| IWO · iShares Trust | 0,02% | 823.535 SH | 8 de Agosto de 2026 | Diário |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,01% | 118.938 SH | 8 de Agosto de 2026 | Diário |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 575.834 SH | 8 de Agosto de 2026 | Diário |
| VHT · VANGUARD WORLD FUND | 0,01% | 461.967 SH | 8 de Agosto de 2026 | Diário |
| IWM · iShares Trust | 0,01% | 2.583.050 SH | 8 de Agosto de 2026 | Diário |
| RSSL · Global X Funds | 0,01% | 42.610 NS | 30 de Abril de 2026 | N-PORT |
| ITWO · ProShares Trust | 0,01% | 4.633 NS | 31 de Maio de 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,01% | 476.309 NS | 31 de Maio de 2026 | N-PORT |
| UWM · ProShares Trust | 0,01% | 3.622 NS | 31 de Maio de 2026 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,00% | 32.379 NS | 31 de Maio de 2026 | N-PORT |
| URTY · ProShares Trust | 0,00% | 3.660 NS | 31 de Maio de 2026 | N-PORT |
| IWN · iShares Trust | 0,00% | 120.119 SH | 8 de Agosto de 2026 | Diário |
| HDG · ProShares Trust | 0,00% | 92 NS | 31 de Maio de 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,00% | 2.922 NS | 31 de Maio de 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 96.350 NS | 31 de Maio de 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 19.020 SH | 8 de Agosto de 2026 | Diário |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 1.100.306 SH | 8 de Agosto de 2026 | Diário |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 4.890.144 SH | 8 de Agosto de 2026 | Diário |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,00% | 9.046 SH | 8 de Agosto de 2026 | Diário |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 7.608 SH | 8 de Agosto de 2026 | Diário |